On this page
This entry or formulation may be investigational and may not correspond to an FDA-approved product; safety and efficacy may not have been established. Kairo lists it for identification and record-keeping only.
Overview
Product & regulatory status
Research entry: inclusion is for identification, not approval or a recommendation to use it. Verify the exact product and current US status with a pharmacist.
What the evidence shows
Individual studies are not combination trials
The linked trials studied long-acting CJC-1295 and intravenous ipamorelin separately, in different populations. Neither establishes the effects of this no-DAC combination. [1]
Different outcomes
The ipamorelin trial assessed recovery of bowel function after surgery, not sleep or muscle growth. [2]
Separate trials are not a combination trial
Long-acting CJC-1295 studies measured hormones in healthy adults, whereas the cited ipamorelin trial studied recovery after bowel surgery. Neither design tests the combined product named here or shows an added benefit from combining them. [2]
What remains unknown
Claims of a “cleaner” pulse, predictable body changes, or improved sleep are not established by these sources.
Safety
Reported safety concerns
FDA reports increased heart rate and systemic vasodilatory reactions associated with CJC-1295. [3]
Confirm the CJC variant and combination
The CJC-1295 paper concerns the long-acting analog. A blend label may describe a different CJC variant. Its identity, ingredients, and formulation need confirmation before any study can be considered relevant. [1]
Understanding product quality
Compounded drugs are not FDA-approved finished products. Poor preparation can cause contamination or incorrect strength. A catalog entry or a research paper is not a quality assessment of your product. [4]
When to seek urgent help
Severe allergic symptoms such as trouble breathing, throat or tongue swelling, or fainting need immediate help. Call 911 or your local emergency number. This is general emergency information, not a complete list of risks for this compound. [5]
A starting point for discussion
This is not a complete list of adverse effects or interactions. Your health history, other medicines, and the exact formulation matter. Missing safety data is not evidence of safety.
Common questions
Is this an evidence-based synergy?
The cited studies do not test synergy. Showing each ingredient affects a signaling pathway does not demonstrate that the combination produces better outcomes or is safe.
Questions for your clinician
Does the evidence match my condition and this exact product? What risks or interactions matter for me? How would we assess whether it is helping?
Sources
- Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults2006 · randomized human trials · PMID 16352683
- Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients2014 · randomized human trial · PMID 25331030
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety RisksFDA · safety information · accessed September 2026
- Compounding and the FDA: Questions and AnswersFDA · product quality and regulation
- AnaphylaxisMedlinePlus · recognizing an emergency
Educational information, not a recommendation to use a compound. Kairo does not give dosing advice. Review decisions with a licensed healthcare professional.